Latest News

Long-term data from the phase 2 TROG 15.03 FASTRACK II trial support the safety and efficacy of stereotactic ablative body radiotherapy for primary renal cell carcinoma.

Jonathan D. Harper, MD, discusses findings from a secondary analysis of the PUSH trial showing that modest increases in urine volume and lower urine osmolality were associated with reduced kidney stone recurrence, even when patients did not reach the guideline-recommended urine output target.

The approval adds another commercially available source of the PSMA-targeted radiotracer.

Kevin C. Zorn, MD, FRCSC, FACS, discusses the factors that clinicians should consider when selecting among different MIST options for BPH.

In this episode, Amy Pearlman, MD, and Annah J. Vollstedt, MD, discuss emerging innovations in female pelvic medicine, including implantable tibial nerve stimulation, the role of pelvic floor physical therapy, and the future of incontinence care.

In this video, Nicole L. Miller, MD, FACS, discusses her approach to assessing patients after prior treatment failure for benign prostatic hyperplasia.

The addition of aglatimagene and valacyclovir to radiotherapy with or without ADT significantly improved disease-free survival in patients with intermediate- to high-risk localized prostate cancer.

Abigail Keller, MD, shares findings showing that nadofaragene firadenovec is associated with increased urine production during instillation compared with gemcitabine/docetaxel.

Clint D. Bahler, MD, reflects on key prostate cancer themes from AUA 2026, including the shift toward more personalized care.

The primary end point—12-month DFS rate—was 80% (40/50 evaluable patients; 95% CI, 0.67-0.89), with 2 patients pending assessment and 3 not evaluable.

The pivotal trial is assessing the non-inferiority of the Separo Vessel Sealing System vs conventional mucosal cautery vasectomy.

Praful Ravi, MB, BChir, MRCP, discusses results from PSMAtrack, which assessed changes in PSMA-PET during initial systemic therapy for metastatic hormone-sensitive prostate cancer.

A recap of the FDA submissions and regulatory decisions in urology from May 2026.